# AMLX catalysts: Amylyx Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/amlx/catalysts

> Amylyx Pharmaceuticals, Inc. (AMLX) has no upcoming catalysts in this calendar. The latest recorded is the Amylyx Pharmaceuticals, Inc. earnings report, November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Amylyx Pharmaceuticals, Inc. |
| Ticker | AMLX (Nasdaq) |
| SEC CIK | 1658551 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/amlx |

## Cash runway

Cash $768.1M as of 2026-09-30; quarterly burn $33.7M; about 68.4 months of runway at that rate (XBRL company facts, accession 0001193125-26-448529).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2022 | [AMX0035 FDA approval](https://sec-api.dev/pdufa/amx0035) | AMLX | ALS in adults | completed, approved | "In September 2022, AMX0035 received approval as RELYVRIO by the FDA for the treatment of ALS in adults, and the Company launched RELYVRIO in the U.S. in October 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1658551/000095017025031309/amlx-20241231.htm)) |
| September 29, 2022 | [Relyvrio (sodium phenylbutyrate; taurursodiol) FDA approval](https://sec-api.dev/pdufa/phenylbutyrate-taurursodiol) | AMLX |  | completed, approved | "Relyvrio \| sodium phenylbutyrate/taurursodiol \| 9/29/2022 \| To treat amyotrophic lateral sclerosis (ALS)Press Release (FDA Archive)Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| Dec 2023 | [AMX0035 trial start](https://sec-api.dev/pdufa/amx0035) | AMLX |  | completed | "In December 2023, we initiated the Phase 2b/3 ORION (NCT06122662) clinical trial, a global, randomized, double-blind, placebo-controlled trial of AMX0035 for the treatment of PSP." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1658551/000119312525174948/amlx-20250630.htm)) |
| Apr 2024 | [AMX0035 topline data readout](https://sec-api.dev/pdufa/amx0035) | AMLX |  | completed, missed | "In April 2024, the Company announced that it had started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO and ALBRIOZA (AMX0035) for ALS and remove the product from the market based on topline results from the global Phase 3 PHOENIX trial, which did not meet its prespecified primary and secondary endpoints." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1658551/000095017025031309/amlx-20241231.htm)) |
| Oct 2024 | [AMX0035 topline data readout](https://sec-api.dev/pdufa/amx0035) | AMLX |  | completed, positive | "In October 2024, we announced positive topline data from the Phase 2 open-label HELIOS (NCT05676034) clinical trial of AMX0035 in 12 adults living with Wolfram syndrome." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1658551/000119312526448529/amlx-20260930.htm)) |
| Feb 2025 | [AMX0114 trial start](https://sec-api.dev/pdufa/amx0114) | AMLX |  | completed | "In February 2025, we started recruiting for the Phase 1 LUMINA clinical trial (NCT06665165), a multicenter, randomized, placebo-controlled, multiple ascending dose trial designed to evaluate the safety and biological activity of AMX0114." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1658551/000095017025066363/amlx-20250331.htm)) |
| Feb 2025 | [Avexitide trial start](https://sec-api.dev/pdufa/avexitide) | AMLX |  | completed | "In February 2025, we started recruiting for the pivotal Phase 3 LUCIDITY clinical trial for avexitide in PBH." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1658551/000095017025066363/amlx-20250331.htm)) |
| March 4, 2025 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000095017025031303/amlx-ex99_1.htm)) |
| Apr 2025 | [AMX0114 trial start](https://sec-api.dev/pdufa/amx0114) | AMLX |  | completed | "In April 2025, we dosed the first participant in Canada for the Phase 1 LUMINA clinical trial (NCT06665165), a multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose trial designed to evaluate the safety and biological activity of AMX0114 in people living with ALS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1658551/000119312525268059/amlx-20250930.htm)) |
| Apr 2025 | [Avexitide trial start](https://sec-api.dev/pdufa/avexitide) | AMLX |  | completed | "In April 2025, we dosed the first participant for the pivotal Phase 3 LUCIDITY clinical trial for avexitide in PBH following RYGB surgery." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1658551/000119312525268059/amlx-20250930.htm)) |
| May 8, 2025 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000095017025066355/amlx-ex99_1.htm)) |
| Q3 2025 | [AMX0035 interim data readout](https://sec-api.dev/pdufa/amx0035) | AMLX |  | scheduled | "Efficacy and safety data from an unblinded interim analysis of the Phase 2b portion of the Phase 2b/3 ORION trial of AMX0035 in PSP is anticipated in the third quarter of 2025, which will be used to inform a go/no-go decision on the Phase 3 portion of the trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1658551/000119312525174948/amlx-20250630.htm)) |
| August 7, 2025 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000095017025104546/amlx-ex99_1.htm)) |
| September 30, 2025 | [AMX0035 primary completion](https://sec-api.dev/pdufa/amx0035) | AMLX | Progressive Supranuclear Palsy; PSP; Neurodegenerative Diseases | completed | "NCT06122662 (AMX0035 and Progressive Supranuclear Palsy): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-09-30 (ACTUAL); Lead Sponsor Amylyx Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122662)) |
| November 6, 2025 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/amlx-ex99_1.htm)) |
| 1H 2026 | [Avexitide topline data readout](https://sec-api.dev/pdufa/avexitide) | AMLX |  | scheduled | "Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated in first half of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000095017025104546/amlx-ex99_1.htm)) |
| March 3, 2026 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086629/amlx-ex99_1.htm)) |
| May 7, 2026 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526210286/amlx-ex99_1.htm)) |
| 2H 2026 | [AMX0035 trial start](https://sec-api.dev/pdufa/amx0035) | AMLX |  | scheduled | "Separately, we are advancing the clinical development of AMX0035 in Wolfram syndrome, and pending alignment with the FDA, we plan to initiate a focused, pivotal Phase 3 clinical trial in the second half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/amlx-ex99_1.htm)) |
| July 8, 2026 | [Avexitide primary completion](https://sec-api.dev/pdufa/avexitide) | AMLX | Post Bariatric Hypoglycemia | completed | "NCT06747468 (Avexitide for Treatment of Post-Bariatric Hypoglycemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-08 (ACTUAL); Lead Sponsor Amylyx Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06747468)) |
| August 6, 2026 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-ex99_1.htm)) |
| August 18, 2026 | [Avexitide topline data readout](https://sec-api.dev/pdufa/avexitide) | AMLX |  | completed, positive | "On August 18, 2026, the Company announced positive topline results from LUCIDITY, a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide, an investigational, first-in-class glucagon-like peptide-1 ("GLP-1") receptor antagonist, in participants with post-bariatric hypoglycemia ("PBH") following Roux-en-Y gastric bypass ("RYGB") surgery." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1658551/000119312526354716/d180533d8k.htm)) |
| late 2026 | [Avexitide NDA/BLA submission](https://sec-api.dev/pdufa/avexitide) | AMLX |  | scheduled | "Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526448525/amlx-ex99_1.htm)) |
| Sep 2026 | [Avexitide topline data readout](https://sec-api.dev/pdufa/avexitide) | AMLX |  | scheduled | "Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August or early September 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-ex99_1.htm)) |
| November 5, 2026 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526448525/amlx-ex99_1.htm)) |

## Drugs

- [AMX0035](https://sec-api.dev/pdufa/amx0035): als in adults, Progressive Supranuclear Palsy
- [AMX0114](https://sec-api.dev/pdufa/amx0114): 
- [Avexitide](https://sec-api.dev/pdufa/avexitide): post-bariatric hypoglycemia, Post Bariatric Hypoglycemia
- [Relyvrio (sodium phenylbutyrate; taurursodiol)](https://sec-api.dev/pdufa/phenylbutyrate-taurursodiol): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/amlx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AMLX catalysts: Amylyx Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/amlx/catalysts

```bibtex
@misc{secapidev_companies_amlx_catalysts_20261116,
  title        = {AMLX catalysts: Amylyx Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/amlx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_amlx_catalysts_20261116","title":"AMLX catalysts: Amylyx Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/amlx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
